Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Allergy
Published in: Clinical and Translational Allergy 1/2015

Open Access 01-12-2015 | Research

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany

Authors: Bram G Verheggen, Kirsten Y Westerhout, Carl H Schreder, Matthias Augustin

Published in: Clinical and Translational Allergy | Issue 1/2015

Login to get access

Abstract

Background

Allergoids are chemically modified allergen extracts administered to reduce allergenicity and to maintain immunogenicity. Oralair® (the 5-grass tablet) is a sublingual native grass allergen tablet for pre- and co-seasonal treatment. Based on a literature review, meta-analysis, and cost-effectiveness analysis the relative effects and costs of the 5-grass tablet versus a mix of subcutaneous allergoid compounds for grass pollen allergic rhinoconjunctivitis were assessed.

Methods

A Markov model with a time horizon of nine years was used to assess the costs and effects of three-year immunotherapy treatment. Relative efficacy expressed as standardized mean differences was estimated using an indirect comparison on symptom scores extracted from available clinical trials. The Rhinitis Symptom Utility Index (RSUI) was applied as a proxy to estimate utility values for symptom scores. Drug acquisition and other medical costs were derived from published sources as well as estimates for resource use, immunotherapy persistence, and occurrence of asthma. The analysis was executed from the German payer’s perspective, which includes payments of the Statutory Health Insurance (SHI) and additional payments by insurants. Comprehensive deterministic and probabilistic sensitivity analyses and different scenarios were performed to test the uncertainty concerning the incremental model outcomes.

Results

The applied model predicted a cost-utility ratio of the 5-grass tablet versus a market mix of injectable allergoid products of € 12,593 per QALY in the base case analysis. Predicted incremental costs and QALYs were € 458 (95% confidence interval, CI: € 220; € 739) and 0.036 (95% CI: 0.002; 0.078), respectively. Compared to the allergoid mix the probability of the 5-grass tablet being the most cost-effective treatment option was predicted to be 76% at a willingness-to-pay threshold of € 20,000. The results were most sensitive to changes in efficacy estimates, duration of the pollen season, and immunotherapy persistence rates.

Conclusions

This analysis suggests the sublingual native 5-grass tablet to be cost-effective relative to a mix of subcutaneous allergoid compounds. The robustness of these statements has been confirmed in extensive sensitivity and scenario analyses.
Appendix
Available only for authorised users
Literature
1.
2.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160.CrossRefPubMed
3.
Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130(5):1049–62.CrossRefPubMed
4.
Pawankar R, Canonica G, Holgate S, Lockey R. WAO White Book on Allergy 2011–2012. 2012.
5.
Ring J, Bachert C, Bauer C, Czech W. Weißbuch allergie in Deutschland. 2010.
6.
Langen U, Schmitz R, Steppuhn H. Häufigkeit allergischer Erkrankungen in Deutschland. Bundesgesundheitsblatt. 2013;56(5–6):698–706.CrossRef
7.
Togias AG. Systemic immunologic and inflammatory aspects of allergic rhinitis. J Allergy Clin Immunol. 2000;106(5 Suppl):S247–50.CrossRefPubMed
8.
Druce H. Allergic and nonallergic rhinitis. In: Middleton E, Reed CE, Ellis EF, Adkinson Jr NF, Yunginger JW, Busse WW, editors. Allergy: principles and practice. 5th ed. St. Louis: Mosby-Year Book; 1998. p. 1005–16.
9.
Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S103–15.CrossRefPubMed
10.
Price D, Bond C, Bouchard J, Costa R, Keenan J, Levy ML, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J. 2006;15(1):58–70.CrossRefPubMed
11.
Kleine-Tebbe J, Bufe A, Ebner C, Eigenmann P, Friedrichs F, Fuchs T, et al. Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen. Leitlinie der Deutschen Gesellschaft Allergologie und kinische Immunologie (DGAKI). Allergo J. 2009;18:508–37.
12.
Interdisziplinäre Arbeitsgruppe “Allergische Rhinitis” der Sektion HNO. Allergische Rhinokonjunktivitis. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI). Allergo J. 2003;12:182–94.
13.
Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118(2):434–40.CrossRefPubMed
14.
Dutch Medicines Evaluation Board. Summary of Product Characteristics (ORALAIR). 2010. p. 1–13.
15.
Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ. 2012;15(5):906–17.CrossRefPubMed
16.
Stiftung Deutscher Polleninformationsdienst. Gesamtdeutscher Pollenflugkalender. Mai: Bad Lippspringe; 2011.
17.
Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol. 2012;130(5):1097–107. e1092.CrossRefPubMed
18.
Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338–45.CrossRefPubMed
19.
Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(1):160–6. e163.CrossRefPubMed
20.
Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128(3):559–66.CrossRefPubMed
21.
Cox LS, Casale TB, Nayak AS, Bernstein DI, Creticos PS, Ambroisine L, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130(6):1327–34. e1321.CrossRefPubMed
22.
Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy. 2012;67(2):272–9.CrossRefPubMed
23.
Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005;60(6):801–7.CrossRefPubMed
24.
Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001;56(6):498–505.CrossRefPubMed
25.
DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 2011;32(3):239–47.CrossRefPubMed
26.
Brewczynski P, Kroon A. Wirksamkeit und Verträglichkeit einer Immuntherapie mit modifizierten Gräserpollenallergenen. Allergologie. 1999;22:411–20.
27.
Sieber J, De Geest S, Shah-Hosseini K, Mosges R. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin. 2011;27(4):855–61.CrossRefPubMed
28.
Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049–57.CrossRefPubMed
29.
Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7.CrossRefPubMed
30.
Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6.CrossRefPubMed
31.
Statistisches Bundesamt Deutschland: Sterbetafel Deutschland. In: Bevölkerung und Erwerbstätigkeit. Wiesbaden; 2012.
32.
33.
Revicki DA, Leidy NK, Brennan-Diemer F, Thompson C, Togias A. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res. 1998;7(8):693–702.CrossRefPubMed
34.
Bruggenjurgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol. 2008;101(3):316–24.CrossRefPubMed
35.
Bernert S, Fernandez A, Haro JM, Konig HH, Alonso J, Vilagut G, et al. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. Value Health. 2009;12(5):750–8.CrossRefPubMed
36.
Allergopharma GmbH: SPC Allergovit Pollen:1–8; Reinbek 2014
37.
LETI Pharma/Novartis Pharma: Fachinformation Depiquick:1–3; Witten/Nürnberg 2014
38.
HAL Allergie GmbH: Fachinformation Purethal Pollenpräparate; Düsseldorf 2013
39.
Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy. 2007;37(5):772–9.CrossRefPubMed
40.
Kassenärztliche Vereinigung Nordrhein (KVNO): Fallwerte/Durchschnittliche Fallzahlen. Regelleistungsvolumen und qualifikationsgebundene Zusatzvolumen. 2/2013; Düsseldorf 2013
41.
Kassenärztliche Bundesvereinigung Berlin (KBV): Einheitlicher Bewertungsmaßstab (EBM) 2/2013. Berlin 2013
42.
Gebührenordnung für Ärzte (GOÄ) online: Arztkosten online. Gutermann Publisher Ltd. Flein; May 2013
43.
Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy. 2010;65(5):668–9.CrossRefPubMed
44.
European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). Summary report: Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe. 2005.
45.
Kirsch F, Teuner CM, Menn P, Leidl R. [Costs of illness for asthma and COPD in adults in Germany]. Gesundheitsw (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)). 2013;75(7):413–23.CrossRef
46.
Statistisches Bundesamt Deutschland. Harmonized consumer price index. Wiesbaden 2013
47.
Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach KW. Asthma: prevalence and cost of illness. European Respiratory Journal. 2005;25(1):47–53.CrossRefPubMed
48.
Institute for Quality and Efficiency in Health Care (IQWiG). General Methods for the Assessment of the Relation of Benefits to Costs. V1.0. 2009.
49.
Statistisches Bundesamt: Yearly estimation of labour costs; Wiesbaden 2013
50.
Petersen KD, Kronborg C, Larsen JN, Dahl R, Gyrd-Hansen D. Patient related outcomes in a real life prospective follow up study: Allergen immunotherapy increase quality of life and reduce sick days. World Allergy Org J. 2013;6(1):15.CrossRef
51.
Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125(1):131–8. e131-137.CrossRefPubMed
52.
Didier A, Malling HJ, Worm M, Horak F, Sussman G, Melac M, et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy. 2013;43(5):568–77.CrossRefPubMed
53.
Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med. 2007;101(9):1885–94.CrossRefPubMed
54.
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8.CrossRefPubMed
55.
Lüderitz-Püchel U, Keller-Stanislawskim B, Haustein D. Risk Reevaluation of Diagnostic and Therapeutic Allergen Extracts. An analysis of adverse drug reactions from 1991 to 2000. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2001;44:709–18.CrossRef
56.
Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy. 2008;63(12):1624–9.CrossRefPubMed
57.
Keiding H, Jorgensen KP. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Curr Med Res Opin. 2007;23(5):1113–20.CrossRefPubMed
Metadata
Title
Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany
Authors
Bram G Verheggen
Kirsten Y Westerhout
Carl H Schreder
Matthias Augustin
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Clinical and Translational Allergy / Issue 1/2015
Electronic ISSN: 2045-7022
DOI
https://doi.org/10.1186/s13601-015-0045-z

Other articles of this Issue 1/2015

Clinical and Translational Allergy 1/2015 Go to the issue

Review

“The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis”

Brief communication

Influence of the route of exposure and the matrix on the sensitisation potency of a major cows’ milk allergen

Brief communication

Treating chronic spontaneous urticaria using a brief ‘whole person’ treatment approach: a proof-of-concept study

Research

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey

Review

Innate lymphocyte cells in asthma phenotypes

Research

Expression profiling and functional analysis of Toll-like receptors in primary healthy human nasal epithelial cells shows no correlation and a refractory LPS response